164 related articles for article (PubMed ID: 37582236)
1. Forodesine and Riboprine Exhibit Strong Anti-SARS-CoV-2 Repurposing Potential:
Rabie AM; Abdalla M
ACS Bio Med Chem Au; 2022 Dec; 2(6):565-585. PubMed ID: 37582236
[TBL] [Abstract][Full Text] [Related]
2. A Series of Adenosine Analogs as the First Efficacious Anti-SARS-CoV-2 Drugs against the B.1.1.529.4 Lineage: A Preclinical Repurposing Research Study.
Rabie AM; Abdalla M
ChemistrySelect; 2022 Dec; 7(46):e202201912. PubMed ID: 36718467
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a series of nucleoside analogs as effective anticoronaviral-2 drugs against the Omicron-B.1.1.529/BA.2 subvariant: A repurposing research study.
Rabie AM; Abdalla M
Med Chem Res; 2023; 32(2):326-341. PubMed ID: 36593869
[TBL] [Abstract][Full Text] [Related]
4. Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant.
Abdalla M; Rabie AM
Comput Biol Chem; 2023 Jun; 104():107768. PubMed ID: 36842392
[TBL] [Abstract][Full Text] [Related]
5. Potent Dual Polymerase/Exonuclease Inhibitory Activities of Antioxidant Aminothiadiazoles Against the COVID-19 Omicron Virus: A Promising In Silico/In Vitro Repositioning Research Study.
Rabie AM; Eltayb WA
Mol Biotechnol; 2024 Apr; 66(4):592-611. PubMed ID: 36690820
[TBL] [Abstract][Full Text] [Related]
6. Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir "S-217622": A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species.
Eltayb WA; Abdalla M; Rabie AM
ACS Omega; 2023 Feb; 8(6):5234-5246. PubMed ID: 36798145
[TBL] [Abstract][Full Text] [Related]
7. Strong Dual Antipolymerase/Antiexonuclease Actions of Some Aminothiadiazole Antioxidants: A Promising
Rabie AM; Eltayb WA
Adv Redox Res; 2023 Jan; ():100064. PubMed ID: 36776420
[TBL] [Abstract][Full Text] [Related]
8. Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease.
Rabie AM
ACS Omega; 2022 Jun; 7(25):21385-21396. PubMed ID: 35785294
[TBL] [Abstract][Full Text] [Related]
9. Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19.
Rabie AM
Curr Res Pharmacol Drug Discov; 2021; 2():100055. PubMed ID: 34870153
[TBL] [Abstract][Full Text] [Related]
10. 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.
Zhao J; Zhang G; Zhang Y; Yi D; Li Q; Ma L; Guo S; Li X; Guo F; Lin R; Luu G; Liu Z; Wang Y; Cen S
Antiviral Res; 2021 Dec; 196():105209. PubMed ID: 34801588
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and anti-SARS-CoV-2 evaluation of lipid prodrugs of β-D-N
Wen ZH; Wang MM; Li LY; Herdewijn P; Snoeck R; Andrei G; Liu ZP; Liu C
Bioorg Chem; 2023 Jun; 135():106527. PubMed ID: 37031504
[TBL] [Abstract][Full Text] [Related]
12. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
Agostini ML; Andres EL; Sims AC; Graham RL; Sheahan TP; Lu X; Smith EC; Case JB; Feng JY; Jordan R; Ray AS; Cihlar T; Siegel D; Mackman RL; Clarke MO; Baric RS; Denison MR
mBio; 2018 Mar; 9(2):. PubMed ID: 29511076
[TBL] [Abstract][Full Text] [Related]
13. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).
Karthic A; Kesarwani V; Singh RK; Yadav PK; Chaturvedi N; Chauhan P; Yadav BS; Kushwaha SK
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164069
[TBL] [Abstract][Full Text] [Related]
14. Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles.
Rabie AM
Chem Biol Interact; 2021 Jul; 343():109480. PubMed ID: 33887223
[TBL] [Abstract][Full Text] [Related]
15. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
[TBL] [Abstract][Full Text] [Related]
16. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 RdRp uses NDPs as a substrate and is able to incorporate NHC into RNA from diphosphate form molnupiravir.
Wang M; Wu C; Liu N; Zhang F; Dong H; Wang S; Chen M; Jiang X; Zhang K; Gu L
Int J Biol Macromol; 2023 Jan; 226():946-955. PubMed ID: 36528144
[TBL] [Abstract][Full Text] [Related]
18. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M
J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635
[TBL] [Abstract][Full Text] [Related]
19. Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication.
Rabie AM
ACS Omega; 2022 Jan; 7(3):2960-2969. PubMed ID: 35071937
[TBL] [Abstract][Full Text] [Related]
20. Nudix hydrolase 18 catalyzes the hydrolysis of active triphosphate metabolites of the antivirals remdesivir, ribavirin, and molnupiravir.
Jemth AS; Scaletti ER; Homan E; Stenmark P; Helleday T; Michel M
J Biol Chem; 2022 Aug; 298(8):102169. PubMed ID: 35732208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
